# DREAMM-9 (NCT04091126)

> Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: belantamab mafodotin plus bortezomib plus lenalidomide plus dexamethasone
- Indication: newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04091126
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Multiple Myeloma
- Interventions: Belantamab mafodotin; Bortezomib; Lenalidomide; Dexamethasone
- Enrollment: 118
- Primary outcome: Number of participants with dose-limiting toxicities (DLTs)
- Primary outcome: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

## Indexed commentary on DREAMM-9 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 26 posts on X
- 19 YouTube videos
- 3 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=dreamm-9-nct04091126

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04091126", "email": "<work email>"}; the inbox owner confirms by the emailed link.